| pubmed-article:21095491 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21095491 | lifeskim:mentions | umls-concept:C0042960 | lld:lifeskim |
| pubmed-article:21095491 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:21095491 | lifeskim:mentions | umls-concept:C0024554 | lld:lifeskim |
| pubmed-article:21095491 | lifeskim:mentions | umls-concept:C1556095 | lld:lifeskim |
| pubmed-article:21095491 | lifeskim:mentions | umls-concept:C1549078 | lld:lifeskim |
| pubmed-article:21095491 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:21095491 | lifeskim:mentions | umls-concept:C0150097 | lld:lifeskim |
| pubmed-article:21095491 | lifeskim:mentions | umls-concept:C0014822 | lld:lifeskim |
| pubmed-article:21095491 | lifeskim:mentions | umls-concept:C1997894 | lld:lifeskim |
| pubmed-article:21095491 | lifeskim:mentions | umls-concept:C0443315 | lld:lifeskim |
| pubmed-article:21095491 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:21095491 | lifeskim:mentions | umls-concept:C0524527 | lld:lifeskim |
| pubmed-article:21095491 | lifeskim:mentions | umls-concept:C0201734 | lld:lifeskim |
| pubmed-article:21095491 | lifeskim:mentions | umls-concept:C1709518 | lld:lifeskim |
| pubmed-article:21095491 | lifeskim:mentions | umls-concept:C0205171 | lld:lifeskim |
| pubmed-article:21095491 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:21095491 | pubmed:dateCreated | 2010-11-24 | lld:pubmed |
| pubmed-article:21095491 | pubmed:abstractText | Recombinant human erythropoietin is indicated for the treatment of anemia resulting from chronic renal failure or chemotherapy. It is also used for patients at high risk for transfusions because of significant blood loss during surgery. A new recombinant human erythropoietin (epoetin alfa) that excludes fetal bovine serum and human serum albumin from among its ingredients was developed in Korea. This study was planned as part of a product development project at the request of the Korean regulatory agency. | lld:pubmed |
| pubmed-article:21095491 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21095491 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21095491 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21095491 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21095491 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21095491 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21095491 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21095491 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21095491 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:21095491 | pubmed:issn | 1879-114X | lld:pubmed |
| pubmed-article:21095491 | pubmed:author | pubmed-author:YuKyung-SangK... | lld:pubmed |
| pubmed-article:21095491 | pubmed:author | pubmed-author:JangIn-JinIJ | lld:pubmed |
| pubmed-article:21095491 | pubmed:author | pubmed-author:ShinSang-GooS... | lld:pubmed |
| pubmed-article:21095491 | pubmed:author | pubmed-author:KimTae-EunTE | lld:pubmed |
| pubmed-article:21095491 | pubmed:author | pubmed-author:KimKyu-PyoKP | lld:pubmed |
| pubmed-article:21095491 | pubmed:author | pubmed-author:KimBo-HyungBH | lld:pubmed |
| pubmed-article:21095491 | pubmed:copyrightInfo | Copyright © 2010 Excerpta Medica Inc. All rights reserved. | lld:pubmed |
| pubmed-article:21095491 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21095491 | pubmed:volume | 32 | lld:pubmed |
| pubmed-article:21095491 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21095491 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21095491 | pubmed:pagination | 1968-76 | lld:pubmed |
| pubmed-article:21095491 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:21095491 | pubmed:meshHeading | pubmed-meshheading:21095491... | lld:pubmed |
| pubmed-article:21095491 | pubmed:meshHeading | pubmed-meshheading:21095491... | lld:pubmed |
| pubmed-article:21095491 | pubmed:meshHeading | pubmed-meshheading:21095491... | lld:pubmed |
| pubmed-article:21095491 | pubmed:meshHeading | pubmed-meshheading:21095491... | lld:pubmed |
| pubmed-article:21095491 | pubmed:meshHeading | pubmed-meshheading:21095491... | lld:pubmed |
| pubmed-article:21095491 | pubmed:meshHeading | pubmed-meshheading:21095491... | lld:pubmed |
| pubmed-article:21095491 | pubmed:meshHeading | pubmed-meshheading:21095491... | lld:pubmed |
| pubmed-article:21095491 | pubmed:meshHeading | pubmed-meshheading:21095491... | lld:pubmed |
| pubmed-article:21095491 | pubmed:meshHeading | pubmed-meshheading:21095491... | lld:pubmed |
| pubmed-article:21095491 | pubmed:meshHeading | pubmed-meshheading:21095491... | lld:pubmed |
| pubmed-article:21095491 | pubmed:meshHeading | pubmed-meshheading:21095491... | lld:pubmed |
| pubmed-article:21095491 | pubmed:meshHeading | pubmed-meshheading:21095491... | lld:pubmed |
| pubmed-article:21095491 | pubmed:meshHeading | pubmed-meshheading:21095491... | lld:pubmed |
| pubmed-article:21095491 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:21095491 | pubmed:articleTitle | Pharmacokinetic and pharmacodynamic comparison of two recombinant human erythropoietin formulations after single subcutaneous administration: an open-label, sequence-randomized, two-treatment crossover study in healthy Korean male volunteers. | lld:pubmed |
| pubmed-article:21095491 | pubmed:affiliation | Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea. | lld:pubmed |
| pubmed-article:21095491 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21095491 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:21095491 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:21095491 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
